RedHill Biopharma initiates promotion of Esomeprazole Strontium in the U.S.
RedHill Biopharma (RDHL) has initiated promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S. RedHill's U.S. commercial operations are expected to pave the way for the potential future launch of RedHill's late clinical-stage GI products, if approved by the FDA. Esomeprazole Strontium DR Capsules is a product indicated for adults for the treatment of gastroesophageal reflux disease, risk reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce the risk of duodenal ulcer recurrence and for pathological hypersecretory conditions. Esomeprazole Strontium DR Capsules is a proprietary prescription drug approved by the FDA under a New Drug Application. PPIs are one of the most commonly prescribed classes of medications in the U.S., with an estimated market value exceeding $20B in 2016. RedHill has an exclusive co-promotion agreement with Concordia Pharmaceuticals, a subsidiary of Concordia International (CXRX), granting RedHill certain U.S. promotion rights for Donnatal. Under the terms of the agreement, RedHill and Concordia will share the revenues generated from the promotion of Donnatal by RedHill, based on an agreed upon split. RDHL CXRX